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A Conserved Water-Mediated Hydrogen Bond Network Underlies Selec-
tivity of the Kinase Inhibitor Bosutinib
Nicholas M. Levinson, Steven G. Boxer.
Stanford University, Stanford, CA, USA.
Kinase inhibitors are anti-cancer drugs developed to target particular oncogenic
protein kinases, but these molecules display many off-target effects. The devel-
opment of more selective compounds is hindered by our poor understanding of
how sequence variation among kinases affects interactions with inhibitors. Here
we show that the clinical kinase inhibitor bosutinib exploits a conserved water-
mediated hydrogen bond network when it binds to target kinases, and that this
recognition mechanism is a widespread feature of type I kinase inhibitors. We
used the nitrile group of bosutinib as a site-specific infrared probe to study
how substitutions in the ATP-binding site modulate the nitrile’s engagement
in the hydrogen bond network. The particular amino acids found at the gate-
keeper and one other position exert exclusive control, contributing ~2 kcal/
mol to selective binding, and the selectivity profile of the drug across the human
kinome can be systematically rationalized in terms of the impact of these substi-
tutions on the hydrogen bond network. Our work highlights the key importance
of structured water molecules for inhibitor recognition, reveals a new mecha-
nism by which the gatekeeper can control inhibitor selectivity, and showcases
an effective approach for elucidating the molecular origins of selectivity.
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Cancer is a serious illness and the second leading cause of death in the US. It is
caused by misregulation of the signaling cascades and uncontrolled cell prolif-
eration. Protein kinases are the key players in the regulatory machinery, and in
the last 20 years they have become an increasingly important drug targets. The
main requirement for such drugs is selectivity: ideally, only one kinase should
be affected by an individual drug. The prominent success story is an FDA-
approved chronic myeloid leukemia therapeutic Gleevec. Gleevec is a highly
specific inhibitor of the Abl kinase and has very little potency towards a closely
related Src subfamily of kinases. This specificity is particularly intriguing
considering that the drug-binding pockets look nearly identical in these kinases.
We combined NMR and pre-steady-state kinetic experiments to monitor Glee-
vec binding in real time and with residue-specific precision. Our data establish a
novel model that fully and quantitatively explains the observed 3000-fold dif-
ference in Gleevec’s affinities to Abl and Src, solving a long-standing paradox
in the field. These results reveal the general principles of kinase-drug interac-
tions and highlight the molecular mechanisms behind nanomolar affinities
found in clinically relevant therapeutics.
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Finding Hidden Allosteric Sites in Proteins
Gregory R. Bowman, Phillip L. Geissler, Susan Marqusee.
UC Berkeley, Berkeley, CA, USA.
The substantial dynamics that folded proteins undergo creates the potential for
hidden allosteric sites-unexpected pockets capable of altering a protein’s activity
via long-range communicationwith theactive site-that couldbevaluable drug tar-
gets. Unfortunately, identifying these sites and targeting themwith drugs remains
a profound challenge, typically requiring resource intensive screening of large li-
braries of small molecules. Here, I will present a combination of computational
and experimental tools for identifying hidden allosteric sites without having to
consider specific ligands. First, we use atomically-detailed Markov state models
of a ligand-free protein to identify potential allosteric sites based on two signature
structural fluctuations: (i) the presence of a pocket in a non-trivial fraction of the
protein population and (ii) the presence of correlated motions allowing commu-
nication between residues surrounding the pocket and the active site where chem-
istry is performed. Second, we use labeling experiments to test the existence of
proposed pockets. Application of this approach to TEM-1 b-lactamase-an impor-
tant drug target for overcoming antibiotic resistance-demonstrates that these
methods are capable of recovering known hidden allosteric sites. Moreover,
our approach reveals a new allosteric site in b-lactamase that may serve as a valu-
able drug target. Therefore, we propose our methods will be a powerful means of
identifying additional hidden allosteric sites in other proteins.3271-Plat
Computational Prediction of Protein-Peptide Binding
Iris Antes, Manuel Glaser, Atanas Patronov.
Life Sciences, Technical University of Munich, Freising, Germany.
Protein-peptide interactions are crucial for many important biological pro-
cesses, especially during signal transduction, as they regularly trigger signaling
by initiating molecular recognition events. Additionally, peptides are natural
inhibitors for proteins and therefore important lead structures in pharmaceutical
research. Prominent examples for peptide-based drugs are inhibitors of viral
proteases [1, 2].
There exist very few computational approaches, which allow a structure-based
prediction of protein-peptide binding, especially for larger peptides (> 5 amino
acids) and surface-exposed binding sites. We have developed a two-stage
method for this purpose.
During our procedure, we first predict the peptide’s binding site on the protein’s
surface. This step is important, as for many biologically relevant protein-
peptide interactions no structural information is available for the bound com-
plex. Afterwards we sample all possible peptide conformations in the predicted
binding site to identify the bound conformation of the protein-peptide complex
using two methods: IRECS [3, 4], an algorithm for predicting side chain con-
formations, and DynaDock[5], a molecular dynamics-based docking approach,
which allows an efficient description of the protein’s flexibility during protein-
peptide assembly.
The methodology was successfully evaluated in various projects e.g. investi-
gating peptide binding to Hsp70 and MHC proteins [6]. We will give an outline
of the methodology and its application.
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Multivalency is a widespread phenomenon in many biological systems, and
inevitable for specific surface-surface interactions. The influenza virus provides
a suitable system for studying multivalent interactions as it is covered by a
densely packed layer of hemagglutinin (HA), which provides the virus high af-
finity to the host cells glycocalyx by multivalent interactions. To prevent such
interactions and thus, infection, one promising strategy is the use of inhibitors
presenting multiple HA receptors. For efficient inhibition, we investigated the
optimal spatial arrangement, and amount of ligands of multivalent structures,
among others multivalent polyglycerols and DNA-PNA heteroduplexes. Natu-
ral receptors such as sialic acid or peptide fragments from HA antibodies, form
the basis of our multivalent constructs.
In order to determine exact distances between HA binding sites, we intro-
duced bivalent DNA-PNA heteroduplexes, presenting sialic acid with distinct
distances, and thus serving as molecular rulers. Inhibition of fluorescent vi-
rions to red blood cells by heteroduplexes was assessed by flow cytometry
measurement. By this strategy, we determined the spatial arrangement of
sialic acid for optimal binding to virus at angstrom resolution. Microscale
thermophoresis (MST) technology served as an independent and complemen-
tary approach to assess binding. Here, we detected nanomolar dissociation
constants to full virus particles free in solution. In some instances, we
observed multiphasic binding kinetics of multivalent structures to influenza
virions. These studies are not only highly relevant for inhibition of virus infec-
tion, but also to provide new insights on the fundamentals of multivalent
interactions.
